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Gestational pemphigoid (PG), a very rare pregnancy-
associated bullous dermatosis, is associated with adverse 
pregnancy outcome (miscarriage, preterm delivery, foe-
tal growth restriction). The major antigen in PG is col-
lagen XVII (BP180). PG autoantibodies cross-react with 
collagen XVII in the skin and have been suggested to 
cause placental failure. On this basis, we evaluated clini-
cal outcome and morphological and functional placen-
tal data of 12 PG pregnancies in Finland during 2002 to 
2011. The placental-to-birth weight ratio was abnormal 
in half of the pregnancies. Ultrastructural analysis of PG 
placentas showed detachment of basement membranes 
and undeveloped hemidesmosomes. Ultrasound evalua-
tions of placental function prior to delivery were normal 
in all but one pregnancy. Three (25%) neonates were de-
livered preterm after 35 gestational weeks and one preg-
nancy was complicated by preeclampsia and severe foe-
tal growth restriction. Neonatal outcome was uneventful 
in every case. In conclusion, in pregnancies complicated 
by PG, slight alteration in ultrastructural morphology 
of the placental basement membrane was detected, but 
umbilical artery Doppler evaluation indicated no func-
tional placental changes. Key words: pemphigoid gesta-
tionis; BP180; collagen XVII; placenta; umbilical artery; 
ultrasound; pregnancy outcome.
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Pemphigoid gestationis (PG) is a rare pregnancy-asso-
ciated bullous dermatosis with an incidence of approxi-
mately 1:50,000 pregnancies (1). It typically manifests 
in the second and third trimesters, but may develop at 
any stage during pregnancy and puerperium. Clinically, 
PG is characterized by severe pruritus, urticarial papules, 
plaques and subsequent blister development. The diag-
nostic hallmark of PG is linear C3 deposition along the 
basement membrane in the immunofluorescence staining 
of perilesional skin. Concomitant IgG depositions and 
circulating serum IgG autoantibodies are also typical 
for PG (2, 3). The major antigen in PG is collagen XVII 
(BP180), which is a transmembrane component of the 
hemidesmosome complex mediating the adhesion of 
epithelial cells to the basement membrane (4–6). Colla-
gen XVII is predominantly expressed in skin, but is also 
present in amniotic epithelia, placenta and amniotic fluid 
(7, 8). In PG, autoantibodies are mainly targeted against 
the largest non-collagenous domain NC16A (9–12). The 
exact pathomechanism of PG remains unclear, but ab-
normal expression of MCH II (major histocompatibility 
complex) molecules in PG placenta has been suggested 
to trigger local allogeneic reaction against the feto-pla-
cental unit (13). PG autoantibodies are thought to cause 
placental failure and cross-react with collagen XVII in 
skin (14, 15). In clinical practice, PG does not increase 
foetal mortality, but an association with miscarriage, 
preterm delivery and foetal growth restriction has been 
reported (16–18).
Due to a possible placental failure and the known asso-
ciation of PG with placenta-originated adverse pregnancy 
outcomes, we wanted to evaluate morphological and 
functional placental data as well as the clinical outcome 
of 12 PG pregnancies in Finland during 2002 to 2011. 
MATERIALS AND METHODS
Patients
Finnish dermatologists in all university and central hospitals 
were informed about this prospective PG study, which was 
approved by the ethics committee of Northern Ostrobothnia 
Hospital District, Oulu, Finland. Ten Finnish (Caucasian) 
patients with 12 pregnancies were recruited, and an informed 
consent was requested after the confirmation of PG diagnosis 
in the local units in 2002 to 2011. Inclusion criteria included 
typical cutaneous findings for PG and C3 positivity in direct 
immunofluorescence analysis of perilesional skin. Direct im-
munofluorescence analysis of skin and placental (patient 7) 
samples were performed using standard procedures. Clinical 
outcome data was collected from the patient records. The study 
was performed according to the Declaration of Helsinki 1983 
and approved by the ethics committee of Northern Ostrobothnia 
Hospital District (reference number 61/2004). In addition, all 
participating women gave informed consent for use of their 
medical data for research purposes.
Blood sampling and transmission electron microscopy of the 
placenta
Circulating antibodies against collagen XVII were analysed in 
6 out of 12 pregnancies by BP180-ELISA (Medical & Biolo-
gical Laboratories, Nagoya, Japan) performed at HUSLAB in 
Helsinki, Finland. 
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Transmission electron microscopic analysis of placental samp-
les from 5 PG placentas and control placentas collected from 
uneventful pregnancies at Oulu University Hospital, Oulu, was 
performed by a single observer. The sample preparation for trans-
mission electron microscopy has been described earlier (19). 
Ultrasonographic placental examination
Image-directed pulsed and colour Doppler ultrasound equipment 
(Acuson Sequoia 512; Acuson Corporation, Mountain View, 
CA, USA; Voluson Expert 730 and Voluson E8, GE Medical 
Systems, Kretz, Austria) with 4–8 MHz convex probes was used 
to obtain umbilical artery blood velocity waveforms from free 
loops of the umbilical cord. For the qualitative analysis of the 
umbilical artery blood velocity waveforms, the high-pass filter 
was set to a minimum, and the angle of insonation was kept at 
< 15 degrees. The median interval between the ultrasonographic 
examination and delivery was 5 days (range 0–21 days).
RESULTS
Dermatological characteristics of the 12 included preg-
nancies (10 women) are summarized in Table I. We 
have partly described patients 5 and 6 in our previous 
study (8). 
Clinical presentation
All but 2 mothers with PG were multiparous. No PG 
was identified in their previous pregnancies (median 
2 (range 1–3)). The majority of the mothers (58%) 
presented symptoms during the last trimester of preg-
nancy (Table I). Three mothers delivered after the index 
PG pregnancy, and PG developed in 2 (33%) of the 6 
consecutive pregnancies. These 2 pregnancies were the 
only ones in this series with PG onset during the first 
trimester (Table I). Median postnatal follow-up was 
2.0 years (range 0.5–8.7 years).
Pruritus was the principal symptom in all women. 
At the first dermatological visit 7 (58%) women had 
blistering eruptions and subsequently all but one de-
veloped blisters. There was cutaneous involvement 
in the abdomen and periumbilical area in all cases. 
Blisters were detected in the extremities, chest, back, 
areolas, vulva and armpits as well (Table I; see Fig. 1 
for an example). Linear C3 depositions in the basement 
membrane zone were present in all 12 cases. IgG de-
positions were positive in 3 out of 12 (25%) women. 
Linear C3 depositions were also detected in the villous 
trophoblastic basement membrane zone in PG placenta 
(Fig. 2a), but not in normal placenta (data not shown). 
At the onset of PG symptoms at 8–36 gestational weeks, 
anti-BP180-IgG levels were approximately 4–10-fold 
compared with the upper limit of the normal value in 
all cases analysed (n = 6) (Table I).
Systemic corticosteroids were the mainstay treatment. 
Prednisolone at doses of 20–50 mg per day was used 
in 8 out of 12 (66%) cases. Three women (25%) were 
treated successfully with topical corticosteroids and 
antihistaminic agents only, and all patients received 
them in addition to systemic treatment. Cyclosporine 
was added to systemic corticosteroid due to severe PG 
manifestation in case 7. Four (33%) women continued 
systemic corticosteroid treatment longer than one month 
after the delivery. Median (range) length of systemic 
cortisone treatment was 2 weeks (1–10) during preg-
nancy and 2 months (0.5–15) postpartum. Two (17%) 
women reported premenstrual flare-ups, and one of them 
still develops skin symptoms on her feet 6 years after 
the delivery. Two women have used oral contraceptives 
and neither reported further symptoms of PG.
Prenatal testing and pregnancy outcome
Obstetric characteristics of the 12 PG pregnancies 
are presented in Table II. One pregnancy (8%) was 
complicated by preeclampsia and foetal growth below 
the 5th percentile (20). Three (25%) neonates were de-
livered prematurely at > 35 gestational weeks with a 
spontaneous onset of labour. Antenatal evaluations of 
foetal growth, biophysical profile score and Doppler 
ultrasonographic evaluation of placental function were 
normal in all cases but one: foetal growth in the 2nd 





GA at onset 
of symtoms
DIF findings 
(C3/IgG) BP180-ELISAa Sites of involvement (including blisters) Main treatment
Subsequent 
pregnancy
1 35 24+ +/– 50 Abdomen, extremities Prednisolone  
2 32 37+ +/+ NA Abdomen, loins, forearms Prednisolone  
3 35 35+ +/– NA Palms, areolas, vulva, abdomen Topical steroids  
4 32 16+ +/– NA Abdomen, loins, armpits, upper arms Topical steroids  
5 29 37+ +/– 27 Abdomen, extremitiesb Prednisolone One unaffected
6a 21 37+ +/– NA Abdomen, arms, loins Methylprednisolone One affected (6b)
6b 23 8+ +/– 40-67-83 Forearms, lower legs, soles; spreading Methylprednisolone  
7 32 27+ +/+ 77-110-41 Abdomen, trunk, extremities; spreading Prednisolone, Cyclosporine  
8 32 22+ +/– 50 Abdomen, loins, extremities Prednisolone  
9 34 36+ +/+ 43 Abdomen, ankles, wrists Topical steroids  
10a 28 32+ +/– NA Abdomen, palms, soles, arms Prednisolone One affected (10b)
10b 30 10+ +/– NA Feet, soles, palms Topical steroids 3 unaffected
aU/ml, normal reference < 9 U/ml, first values given are at the onset of disease and latter during the course of disease. bNo blisters.
GA: gestational age, weeks; DIF: direct immunofluorescence microscopy; NA: not available.
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percentile, oligohydramnion and decreased diastolic 
velocity in the umbilical artery as a sign of increased 
placental impedance was detected in the pregnancy 
complicated by preeclampsia and foetal growth res-
triction. This neonate was delivered via a Caesarean 
section due to foetal distress during labour. Another 
Caesarean section was performed due to malpresenta-
tion. Normal umbilical artery pH values at birth and 
5-min Apgar scores ≥ 9 were detected in every case. 
Despite normal birth weight percentiles in all but one 
case, the placental-to-birth weight ratio was abnormal 
in half of the PG pregnancies. In 5 cases the placental-
to-birth weight ratio was below the 10th percentile and 
in one case it was above the 90th percentile (Table II) 
(21). Two neonates were followed in the neonatal unit 
after delivery due to respiratory problems without as-
sisted ventilation, but no significant neonatal morbidity 
up to the age of one month was reported. 
Placental ultrastructural findings
Transmission electron microscopy revealed distinct 
hemidesmosomes in trophoblast basal areas in the con-
trol placentas (Fig. 2b), whereas hemidesmosomes in 
PG placenta were less developed (Fig. 2c). Moreover, 
in PG placentas basement membranes were partially 
detached from the trophoblasts (Fig. 2d). 
DISCUSSION
According to previous studies, PG not only affects 
the maternal skin, but may complicate the pregnancy 
through miscarriage, preterm delivery, foetal growth 
Fig. 2. (a) Direct immunofluorescence 
analysis of gestational pemphigoid (PG) 
placenta showed linear C3 positivity 
in the villous trophoblastic basement 
membrane (BM) in patient 7 (20 × original 
magnification).  (b) Transmission electron 
microscopy analysis of normal placenta 
showed well-developed hemidesmosomes 
(asterisk), but (c) in PG placenta hemi-
desmosomes were undeveloped. (d) In 
addition, partial BM microseparation 
(arrows) is observed in PG placenta. T: 
trophoblast; scale bars 500 nm.
Fig. 1. (a) Urticarial papules, plaques and blisters on the abdominal skin and 
thighs of gestational pemphigoid case 7. (b) Normal umbilical artery blood 
flow profile at > 35 gestational weeks.
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restriction and neonatal blistering (15, 22, 23). Cur-
rently, no guidelines exist for PG pregnancy monitoring 
and foetal surveillance. While placental failure has 
been associated with this pregnancy-associated bullous 
dermatosis, we decided to investigate placental mor-
phology and function as well as perinatal outcome in 
12 PG pregnancies in Finland in 2002 to 2011.
In the present study, all but 2 mothers were multi-
parous (83%). This is in line with previous reports, al-
though it is currently unknown why PG is more common 
in multiparous than primiparous women (15, 24). Ten 
(83%) of our patients developed PG in the second and 
third trimesters, which coincidences approximately with 
the 64% proportion in a large British multicentre clinical 
survey (24). In the study by Chi et al. (24), early PG 
onset in the first and second trimesters was associated 
with increased morbidity and decreased gestational age 
at delivery. Among our 2 patients with PG onset in the 
first trimester, only patient 6 demonstrated a more severe 
PG in her subsequent pregnancy and delivered at 35+ 
gestational weeks with normal neonatal outcome, while 
a mild skin eruption in patient 10 healed spontaneously 
over a few weeks. The explanation for this spontaneous 
remission remains unclear. Furthermore, all preterm 
deliveries in this series were identified among 5 mothers 
with PG onset prior to 26 gestational weeks, which is 
in line with the report by Chi et al. (24). A subsequent 
pregnancy with no PG has been reported to be rare, with 
a prevalence of 8% (25). Our high rate of unaffected 
subsequent pregnancies (67%) is most likely due to the 
small number of subsequent pregnancies. In addition, 
ethnic issues, which have not been addressed in previous 
studies, may play a role.
In all cases the first site of PG involvement was 
abdominal skin, and in the majority the onset was peri-
umbilical. Frequent periumbilical involvement has been 
reported earlier (15), albeit Castro et al. (26) reported 
the extremities to be the most frequently affected site. 
Previously, blistering has been associated with adverse 
pregnancy outcome, especially decreased gestational 
age at delivery (24). In this series, however, the num-
ber of preterm deliveries (25%) was not higher than in 
earlier reports (20–34%) despite blister development 
in all cases but one (17, 24). In 2 pregnancies (6b and 
7) skin involvement with blisters was very extensive. 
One of these women delivered at 35+ gestational weeks 
with no significant neonatal morbidity.
In the current study, none of the 3 (25%) preterm neo-
nates who were delivered beyond > 35 gestational weeks 
showed any significant neonatal morbidity. During the 
study period, the percentage of preterm deliveries be-
fore 37+0 gestational weeks in Finland varied between 
5.1% and 5.3% annually (27). This series thus confirms 
earlier data indicating an increased incidence of prema-
ture deliveries in PG pregnancies (15, 17, 18). In our 
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late preeclampsia and foetal growth in approximately 
the 2nd percentile. This is in line with the 8–14% pre-
valence of preeclampsia in various regions in Finland 
(28). We did not observe any maternal pregnancy- or 
non-pregnancy-associated co-morbidity, except in the 
case with preeclampsia. 
Interestingly, the current study demonstrates ab-
normal placental-to-birth weight ratios in 50% of the 
cases, although the birth weight percentiles were nor-
mal in all but one case (Table II) (21). Recent studies 
suggest an association between both low and high 
placental-to-birth weight ratios and higher incidence of 
placenta-originated pregnancy complications and later 
cardiovascular and metabolic morbidity in adulthood 
(29, 30). However, currently there is no data available 
about the later development and morbidity of offspring 
born from PG pregnancies. This study design does not 
allow us to speculate whether abnormal placental-to-
birth weight ratios are due to PG itself or its treatment 
with systemic corticosteroids.
Morphological data on PG placentas is rare. We and 
others have earlier shown that there is an accumulation 
of C3 complement and IgG, mild villitis, and collections 
of immature fibrotic villi in term PG placenta with no 
difference in collagen XVII expression compared with 
normal term placenta (8). In the present study, detach-
ment of the basement membrane in PG placenta and 
undeveloped hemidesmosomes is most probably due to 
autoimmune reaction against placental collagen XVII, 
the main constituent of hemidesmosomes. Also, addi-
tional, non-inflammatory mechanisms may be involved, 
since sera from patients with bullous pemphigoid is 
shown to decrease the expression of collagen XVII in 
cultured keratinocytes (31, 32). Further experiments 
are required to investigate whether pemphigoid auto-
antibodies disturb collagen XVII expression also in 
cultured trophoblasts. In any case, we speculate that 
the current ultrastructural findings could explain the 
slight malfunction of PG placenta leading to adverse 
pregnancy outcomes. 
Adverse foetal outcomes associated with PG are pro-
posed to be caused by a minor placental failure induced 
by autoantibodies against collagen XVII (14). Umbilical 
artery Doppler assessment has been used to evaluate 
placental function in complicated pregnancies. In-
creased umbilical artery pulsatility, decreased diastolic 
velocity and absent or reversed velocity in end-diastole 
are the hallmarks of increased impedance and placental 
malfunction (33, 34). While no guidelines exist for PG 
monitoring, the mothers in this study were referred 
to their obstetricians, who made individual follow-up 
schedules for them. Normal umbilical artery Doppler 
recordings in all except one case and normal neonatal 
outcome suggest that currently available monitoring 
methods do not detect possible placental malfunction 
caused by morphological PG changes. Vascular sprou-
ting of the placental villous tree mainly occurs before 
mid-gestation (35), and PG changes possibly occurring 
not until late in the second and third trimester might 
thus not have a huge impact on placental function. In 
the single case report with umbilical artery Doppler ul-
trasound follow-up in PG, abnormal placental function 
was detected in a PG pregnancy complicated by foetal 
growth restriction (36). Our placental functional data 
and good neonatal outcome in this study suggest, how-
ever, that clinically detectable placental malfunction 
related to PG is rare. Furthermore, systemic steroid 
medication for up to 10 weeks during pregnancy did 
not seem to affect the neonatal outcome. 
In clinical practice, vaginal ultrasound evaluation of 
cervical length and possible opening of the internal cer-
vical os are the gold standards in the prediction of pos-
sible preterm delivery (37). In this series, digital cervical 
examination was normal 5–20 days prior to preterm 
delivery. Although prediction of preterm delivery is dif-
ficult, we propose that, due to an increased incidence of 
preterm deliveries in PG pregnancies, obstetric follow-
up with vaginal ultrasound assessment of cervical length 
is indicated. Our results also suggest that mothers can 
be reassured that good perinatal and neonatal outcome 
with normal birth weight, pH-values, Apgar scores and 
low neonatal morbidity can be expected. 
The sample size of 12 pregnancies naturally limits 
the interpretation of our results. However, the median 
birth rate in Finland during the study period was ap-
proximately 58,000 per year, and we therefore assume 
that we were able to recruit nearly all PG patients 
during 2002 to 2011, as the estimated PG incidence is 
approximately 1:50,000 (1). Naturally, a strict obstetric 
follow-up protocol and a higher number of placentas 
available for morphological analysis would have en-
hanced our findings. 
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